Related Experiment Video
Updated: Feb 18, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
Published on: June 9, 2023
Metformin: a therapeutic opportunity in breast cancer
Ana M Gonzalez-Angulo1, Funda Meric-Bernstam
1Department of Breast Medical Oncology, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas 77030, USA. agonzalez@mdanderson.org
Abstract:
Two important, related pathways are involved in cancer growth: the insulin/insulin-like growth factor-1 (IGF1) signaling pathway, which is activated when nutrients are available, and the adenosine mono-phosphate-activated protein kinase (AMPK) pathway, activated when cells are starved for carbohydrates. Metformin inhibits transcription of key gluconeogenesis genes in the liver, increases glucose uptake in skeletal muscle, and decreases circulating insulin levels. Metformin reduces levels of circulating glucose, increases insulin sensitivity, and reduces insulin resistance-associated hyperinsulinemia. At the level of cell signaling, metformin activates AMPK. There are extensive preclinical data showing the anticancer effects of metformin in all breast cancer subtypes as well as in cytotoxic therapy-resistant models. These data, and the epidemiological and retrospective data supporting the antineoplastic effects of metformin, provide the rationale to study the role of metformin for breast cancer therapy in a variety of clinical settings.
Insights
Metformin, a diabetes drug, shows promise in fighting cancer by activating the AMPK pathway and inhibiting cancer growth pathways. Clinical studies are exploring its role in breast cancer therapy.
Area of Science:
- Oncology
- Metabolic Signaling
- Pharmacology
Background:
- Cancer growth is linked to insulin/IGF-1 and AMPK signaling pathways.
- Metformin influences glucose metabolism and insulin sensitivity.
Purpose of the Study:
- To investigate the anticancer effects of metformin.
- To provide rationale for clinical studies of metformin in breast cancer therapy.
Main Methods:
- Review of preclinical, epidemiological, and retrospective data.
- Analysis of metformin's effects on cellular signaling pathways.
Main Results:
- Metformin inhibits gluconeogenesis and increases glucose uptake.
- Metformin activates the AMPK pathway.
- Preclinical data show metformin's efficacy across breast cancer subtypes and resistant models.
Conclusions:
- Metformin exhibits anticancer properties.
- Evidence supports further clinical investigation of metformin for breast cancer treatment.
Related Concept Videos
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Oral Hypoglycemic Agents: Biguanides and Glitazones
Targeted Cancer Therapies
There are several types of targeted therapies against...
Mitogens and the Cell Cycle
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

